Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)
Status:
Completed
Trial end date:
2017-06-08
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, dose limiting toxicity (DLT), and maximum tolerated
dose (MTD), of FS102(BMS-986186) when administered intravenously (IV) to subjects with
relapsed or refractory solid tumors that overexpress HER2 and who have no standard treatment
options.